PTEN loss in biopsy tissue predicts poor clinical outcomes in prostate cancer

Objectives To determine whether PTEN status in prostate biopsy represents a predictor of intermediate and long‐term oncological outcomes after radical prostatectomy, and whether PTEN status predicts response to androgen deprivation therapy. Methods In a retrospective analysis of 77 men treated by ra...

Full description

Saved in:
Bibliographic Details
Published in:International journal of urology 2014-12, Vol.21 (12), p.1209-1214
Main Authors: Mithal, Prabhakar, Allott, Emma, Gerber, Leah, Reid, Julia, Welbourn, William, Tikishvili, Eliso, Park, Jimmy, Younus, Adib, Sangale, Zaina, Lanchbury, Jerry S, Stone, Steven, Freedland, Stephen J
Format: Article
Language:English
Subjects:
biochemical recurrence
Biomarkers, Tumor - analysis
Biopsy - methods
castration-resistant prostate cancer
Follow-Up Studies
Humans
Male
Middle Aged
North Carolina - epidemiology
Prognosis
prostate cancer
prostate cancer-specific mortality
Prostatic Neoplasms - diagnosis
Prostatic Neoplasms - metabolism
Prostatic Neoplasms - mortality
PTEN
PTEN Phosphohydrolase - analysis
Retrospective Studies
Survival Rate - trends
Time Factors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objectives To determine whether PTEN status in prostate biopsy represents a predictor of intermediate and long‐term oncological outcomes after radical prostatectomy, and whether PTEN status predicts response to androgen deprivation therapy. Methods In a retrospective analysis of 77 men treated by radical prostatectomy who underwent diagnostic biopsy between 1992–2006, biopsy samples were stained for PTEN expression by the PREZEON assay with >10% staining reported as positive. Cox proportional hazards and log–rank models were used to assess the correlation between PTEN loss and clinical outcomes. Results During a median follow‐up period after radical prostatectomy of 8.8 years, 39 men (51%) developed biochemical recurrence, four (5%) had castration‐resistant prostate cancer, two (3%) had metastasis and two (3%) died from prostate cancer. PTEN loss was not significantly associated with biochemical recurrence (hazard ratio 2.1, 95% confidence interval 0.9–5.1, P = 0.10), but significantly predicted increased risk of castration‐resistant prostate cancer, metastasis and prostate cancer‐specific mortality (all log–rank, P 
ISSN:0919-8172
1442-2042
DOI:10.1111/iju.12571